EUVIMEDEUVIMED entdecken
Crossref

Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?

İhsan Kaplan, Halil Kömek, Canan Can, Nadiye Akdeniz, Yunus Güzel, Ferat Kepenek, Ayhan Şenol, Serdar İleri, Hüseyin Karaoğlan, İhsan Solmaz, Mehmet Serdar Yıldırım, Veysi Şenses und 2 weitere

Annals of Nuclear Medicine · 2024

DOI: 10.1007/s12149-024-01954-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2024. Verfasst von İhsan Kaplan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Gazi Yasargil Training and Research Hospital, 21070, Kayapınar, Diyarbakir, Turkey. drihsankaplan@hotmail.com. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Glutamate Carboxypeptidase II, Antigens, Surface, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0. MATERIALS AND METHODS: This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [18F]FDG PET/CT images and whose [18F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient. RESULTS: The 114 patients herein had a median age of 72.5 (51-91) years and a median GS of 8 (7-10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (p < 0.001, p = 0.006, p = 0.003, and p = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1-16.5 months) and 11.8 months (95% CI 7.4-16.2 months), respectively. CONCLUSION: The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyGlutamate Carboxypeptidase IIAntigens, SurfaceProstatic Neoplasms, Castration-ResistantHumansMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

Modified RECIPPSMA PET/CTRECIP 1.0Treatment responseVolumetric parameters

Substanzen

Glutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Gazi Yasargil Training and Research Hospital, 21070, Kayapınar, Diyarbakir, Turkey. drihsankaplan@hotmail.com.
  • Department of Nuclear Medicine, Gazi Yasargil Training and Research Hospital, 21070, Kayapınar, Diyarbakir, Turkey.
  • Department of Internal Medicine, Division of Medical Oncology, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey.
  • Department of Radiology, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey.
  • Department of Internal Medicine, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey.

Zitieren

APA

Kaplan, İ., Kömek, H., Can, C., Akdeniz, N., Güzel, Y., Kepenek, F., Şenol, A., İleri, S., Karaoğlan, H., Solmaz, İ., Yıldırım, M. S., Şenses, V., Kaya, F., & Gündoğan, C. (2024). Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-024-01954-0

Vancouver

Kaplan İ, Kömek H, Can C, Akdeniz N, Güzel Y, Kepenek F, et al. Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?. Annals of Nuclear Medicine. 2024. doi:10.1007/s12149-024-01954-0

BibTeX
@article{Kaplan2024,
  author = {Kaplan, İhsan and Kömek, Halil and Can, Canan and Akdeniz, Nadiye and Güzel, Yunus and Kepenek, Ferat and Şenol, Ayhan and İleri, Serdar and Karaoğlan, Hüseyin and Solmaz, İhsan and Yıldırım, Mehmet Serdar and Şenses, Veysi and Kaya, Fulya and Gündoğan, Cihan},
  title = {Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?},
  journal = {Annals of Nuclear Medicine},
  year = {2024},
  doi = {10.1007/s12149-024-01954-0}
}
Kostenlos starten →